Innoviva Crescita futura

Future criteri di controllo 1/6

Innoviva is forecast to grow revenue at 7.1% per annum.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	18.0%
Tasso di crescita dei ricavi	7.1%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	28 Oct 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:HVE - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	369	N/A	123	116	2
12/31/2025	341	N/A	90	93	2
12/31/2024	339	N/A	N/A	85	2
6/30/2024	330	145	158	158	N/A
3/31/2024	312	181	152	152	N/A
12/31/2023	310	180	141	141	N/A
9/30/2023	290	50	116	117	N/A
6/30/2023	290	233	88	88	N/A
3/31/2023	318	233	129	129	N/A
12/31/2022	331	214	202	202	N/A
9/30/2022	373	293	291	291	N/A
6/30/2022	404	99	372	372	N/A
3/31/2022	396	188	378	378	N/A
12/31/2021	392	266	364	364	N/A
9/30/2021	375	309	351	351	N/A
6/30/2021	365	265	329	329	N/A
3/31/2021	344	253	324	324	N/A
12/31/2020	337	224	313	313	N/A
9/30/2020	322	216	295	295	N/A
6/30/2020	299	228	278	278	N/A
3/31/2020	285	189	254	254	N/A
12/31/2019	261	157	257	257	N/A
9/30/2019	265	375	252	252	N/A
6/30/2019	261	382	255	255	N/A
3/31/2019	264	399	250	250	N/A
12/31/2018	261	395	224	224	N/A
9/30/2018	251	190	210	210	N/A
6/30/2018	238	166	193	193	N/A
3/31/2018	229	147	N/A	164	N/A
12/31/2017	217	134	N/A	142	N/A
9/30/2017	191	101	N/A	115	N/A
6/30/2017	176	92	N/A	92	N/A
3/31/2017	150	72	N/A	81	N/A
12/31/2016	134	60	N/A	61	N/A
9/30/2016	113	38	N/A	47	N/A
6/30/2016	93	19	N/A	29	N/A
3/31/2016	71	-4	N/A	19	N/A
12/31/2015	54	-19	N/A	10	N/A
9/30/2015	38	-39	N/A	-1	N/A
6/30/2015	26	-56	N/A	-25	N/A
3/31/2015	16	-68	N/A	-82	N/A
12/31/2014	8	-74	N/A	-131	N/A
9/30/2014	3	-66	N/A	-166	N/A
6/30/2014	2	-55	N/A	-186	N/A
3/31/2014	2	-9	N/A	-149	N/A
12/31/2013	5	-31	N/A	-130	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if HVE's forecast earnings growth is above the savings rate (0.8%).

Guadagni vs Mercato: Insufficient data to determine if HVE's earnings are forecast to grow faster than the German market

Guadagni ad alta crescita: Insufficient data to determine if HVE's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: HVE's revenue (7.1% per year) is forecast to grow faster than the German market (5.5% per year).

Ricavi ad alta crescita: HVE's revenue (7.1% per year) is forecast to grow slower than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if HVE's Return on Equity is forecast to be high in 3 years time

Innoviva Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

New minor risk - Financial position

New minor risk - Profit margin trend

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

New minor risk - Financial position

Now 21% undervalued after recent price drop

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold €142k worth of stock

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

First quarter 2023 earnings released: EPS: US$0.51 (vs US$0.23 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings released: EPS: US$3.81 (vs US$1.04 in 3Q 2021)

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Second quarter 2022 earnings released: EPS: US$0.013 (vs US$1.01 in 2Q 2021)

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Independent Chairman of the Board recently bought €216k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

New 90-day high: €10.20

New 90-day high: €10.00

Investor sentiment improved over the past week

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP

Third quarter earnings released

New 90-day low: €8.40

New 90-day low: €9.25

New 90-day low - €10.60

New 90-day low - €11.10

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita